About Ran Nussbaum
Ran Nussbaum is a director and 10% owner at LB Pharmaceuticals.
Ran Nussbaum reports to the SEC as a director or major shareholder of 9 public companies, including Keros Therapeutics (KROS), UroGen Pharma (URGN) and Eloxx Pharmaceuticals (ELOX).
Ran Nussbaum first appears on SEC filings in 2014.
Experience
This experience comes from SEC filings. The years are when the filings name Ran Nussbaum in the role, so the role may have started earlier or lasted longer.
KI
Keros Therapeutics, Inc.
Director and 10% owner
2020 – 2025 · Public company (KROS)
UL
UroGen Pharma Ltd.
Director
2019 – 2023 · Public company (URGN)
EI
Eloxx Pharmaceuticals, Inc.
Director
2017 – 2022 · Public company (ELOX)
PI
Prevail Therapeutics Inc.
Director
2019 – 2021 · Public company (PRVL)
AI
Arqule Inc.
Director
2017 – 2020 · Public company (ARQL)
VI
VBI Vaccines Inc
Director
2017 · Public company (VBIV)
KI
Kite Pharma, Inc.
Director
2014 – 2017 · Public company (KITE)
AI
Arno Therapeutics, Inc
10% owner
2016 · Public company (ARNI)
Key Colleagues at Startups
The people Ran Nussbaum works with at each company, as listed on that company's latest Form D.
LB Pharmaceuticals Inc. · Form D/A, Jan 10, 2024
RJ
Rajul Jain
Director
ZP
Zachary Prensky
Chief Executive Officer and director
RR
Robert Ruffolo
Director
AV
Andrew Vaino
Executive officer
AE
Anna Eramo
Executive officer
MP
Marc Panoff
Executive officer
RL
Rebecca Luse
Director
CY
Chen Yu
Director